Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
June 1, 2022
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the